New strategy for untreatable kidney disease: targeting cell energy
By targeting a protein called Polycystin 2, Yale researchers have identified a promising approach for treating autosomal dominant polycystic kidney disease. (Source: Yale Science and Health News)
Source: Yale Science and Health News - May 7, 2019 Category: Universities & Medical Training Source Type: news

Polycystic Kidney Disease: How Much Do You Know?
Autosomal dominant polycystic kidney disease us the most common form of polycystic renal disease. Find out what you know about ADPKD with this 7-question quiz on epidemiology, diagnosis, and more.   (Source: ConsultantLive)
Source: ConsultantLive - May 6, 2019 Category: Internal Medicine Authors: Andrew D. Bowser Tags: Kidney Disease Source Type: news

Polycystic Kidney Disease: What & #039;s Your ADPKD IQ?
Autosomal dominant polycystic kidney disease is the most common form of polycystic renal disease. Find out what you know about ADPKD with this 7-question quiz on epidemiology, diagnosis, and more.   (Source: ConsultantLive)
Source: ConsultantLive - May 6, 2019 Category: Internal Medicine Authors: Andrew D. Bowser Tags: Kidney Disease Source Type: news

Polycystin 2 regulates mitochondrial Ca2+ signaling, bioenergetics, and dynamics through mitofusin 2
Mitochondria and the endoplasmic reticulum (ER) have an intimate functional relationship due to tethering proteins that bring their membranes in close (~30 nm) apposition. One function of this interorganellar junction is to increase the efficiency of Ca2+ transfer into mitochondria, thus stimulating mitochondrial respiration. Here, we showed that the ER cation-permeant channel polycystin 2 (PC2) functions to reduce mitochondria-ER contacts. In cell culture models, PC2 knockdown led to a 50% increase in mitofusin 2 (MFN2) expression, an outer mitochondrial membrane GTPase. Live-cell super-resolution and electron microscopy ...
Source: Signal Transduction Knowledge Environment - May 6, 2019 Category: Science Authors: Kuo, I. Y., Brill, A. L., Lemos, F. O., Jiang, J. Y., Falcone, J. L., Kimmerling, E. P., Cai, Y., Dong, K., Kaplan, D. L., Wallace, D. P., Hofer, A. M., Ehrlich, B. E. Tags: STKE Research Articles Source Type: news

An international prize honors Bradley Yoder for research in polycystic kidney disease
(University of Alabama at Birmingham) Bradley K. Yoder, Ph.D., professor and chair of the Department of Cell, Developmental and Integrative Biology at the University of Alabama at Birmingham, has been awarded with a Lillian Jean Kaplan International Prize for Advancement for his significant research in the polycystic kidney field. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - April 29, 2019 Category: Biology Source Type: news

Infographic: Polycystic kidney disease (PKD)
Learn more about polycystic kidney disease. Other health tip infographics: mayohealthhighlights.startribune.com? (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - February 6, 2019 Category: Databases & Libraries Source Type: news

Tolvaptan listed for polycystic kidney disease in Australia
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - January 1, 2019 Category: Drugs & Pharmacology Source Type: news

Seeing is believing: Monitoring real time changes during cell division
(Lancaster University) Scientist have cast new light on the behaviour of tiny hair-like structures called cilia found on almost every cell in the body. Cilia play important roles in human development and disease. Akin to tiny antennae, they act as cell timers keeping the brakes on cell division until the right growth cues are received. Malfunction of cilia leads to many human diseases such as polycystic kidney disease and cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 19, 2018 Category: Cancer & Oncology Source Type: news

#MayoClinicRadio podcast: 10/20/18
Listen: Mayo Clinic Radio 10/20/18 On the Mayo Clinic Radio podcast, Katherine Zeratsky, a registered dietitian and nutritionist at Mayo Clinic, discusses juicing, lectins and other diet trends.?Also on the podcast, Dr. Fouad Chebib, a nephrologist at Mayo Clinic, explains polycystic kidney disease.?And Dr. Dawn Davis, a dermatologist at Mayo Clinic, discusses diseases of the [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - October 22, 2018 Category: Databases & Libraries Source Type: news

3-year-old girl gets life-saving birthday gift: a new liver and kidney
Lilah Joiner, from Carthage, Mississippi, was born with autosomal recessive polycystic kidney disease (ARPKD). (Source: ABC News: Health)
Source: ABC News: Health - October 4, 2018 Category: Consumer Health News Tags: GMA Source Type: news

Structure of the human PKD1-PKD2 complex
Mutations in two genes, PKD1 and PKD2, account for most cases of autosomal dominant polycystic kidney disease, one of the most common monogenetic disorders. Here we report the 3.6-angstrom cryo–electron microscopy structure of truncated human PKD1-PKD2 complex assembled in a 1:3 ratio. PKD1 contains a voltage-gated ion channel (VGIC) fold that interacts with PKD2 to form the domain-swapped, yet noncanonical, transient receptor potential (TRP) channel architecture. The S6 helix in PKD1 is broken in the middle, with the extracellular half, S6a, resembling pore helix 1 in a typical TRP channel. Three positively charged,...
Source: ScienceNOW - September 6, 2018 Category: Science Authors: Su, Q., Hu, F., Ge, X., Lei, J., Yu, S., Wang, T., Zhou, Q., Mei, C., Shi, Y. Tags: Biochemistry, Online Only r-articles Source Type: news

Tolvaptan Works Long Term in Autosomal Dominant Polycystic Kidney Disease Tolvaptan Works Long Term in Autosomal Dominant Polycystic Kidney Disease
A new study demonstrates the long-term efficacy of the vasopressin-2 receptor antagonist tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD).Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 20, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Kidney disease treatment with roots in KC wins approval after 36 years
The Food and Drug Administration gave the green light for the first approved treatment for polycystic kidney disease on Tuesday — a treatment based on research that traces its roots to Kansas City. In the 1960s, late nephrologist and University of Kansas Medical Center Researcher Dr. Jared Grantham discovered the kidney’s components during a research fellowship. Later on, he found a signaling molecule called cyclic AMP that affects the cell growth and fluid secretion in kidneys. This discovery… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 25, 2018 Category: Biotechnology Authors: Elise Reuter Source Type: news

Kidney disease treatment with roots in KC wins approval after 36 years
The Food and Drug Administration gave the green light for the first approved treatment for polycystic kidney disease on Tuesday — a treatment based on research that traces its roots to Kansas City. In the 1960s, late nephrologist and University of Kansas Medical Center Researcher Dr. Jared Grantham discovered the kidney’s components during a research fellowship. Later on, he found a signaling molecule called cyclic AMP that affects the cell growth and fluid secretion in kidneys. This discovery… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 25, 2018 Category: Pharmaceuticals Authors: Elise Reuter Source Type: news

FDA Approves Jynarque (tolvaptan) to Slow Kidney Function Decline in Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease
April 24, 2018 -- TOKYO--(BUSINESS WIRE)--Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that the U.S. Food and Drug Administration (FDA) has approved Jynarque (tolvaptan) as the first drug treatment to slow kidney function decline in adults at... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 24, 2018 Category: Drugs & Pharmacology Source Type: news